BDBM455552 (S)-1-(4-(4-(1-((R)-1-cyclopropylpropyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl)-1H-pyrazol-1-yl)propan-2-ol::US10730880, Example 218::US11028093, Example 218

SMILES CCC(C1CC1)n1cc(cn1)-c1nc(cn2nccc12)-c1cnn(C[C@H](C)O)c1

InChI Key InChIKey=LZEQHKULKROZGJ-UHFFFAOYSA-N

Data  8 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 8 hits for monomerid = 455552   

TargetTyrosine-protein kinase JAK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM455552(US10730880, Example 218 | (S)-1-(4-(4-(1-((R)-1-cy...)
Affinity DataIC50: 55nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM455552(US10730880, Example 218 | (S)-1-(4-(4-(1-((R)-1-cy...)
Affinity DataIC50: 55nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Tyk2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM455552(US10730880, Example 218 | (S)-1-(4-(4-(1-((R)-1-cy...)
Affinity DataIC50: 55nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Tyk2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM455552(US10730880, Example 218 | (S)-1-(4-(4-(1-((R)-1-cy...)
Affinity DataIC50: 55nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Array Biopharma

US Patent
LigandPNGBDBM455552(US10730880, Example 218 | (S)-1-(4-(4-(1-((R)-1-cy...)
Affinity DataIC50: 550nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK1 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Array Biopharma

US Patent
LigandPNGBDBM455552(US10730880, Example 218 | (S)-1-(4-(4-(1-((R)-1-cy...)
Affinity DataIC50: 550nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK1 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Array Biopharma

US Patent
LigandPNGBDBM455552(US10730880, Example 218 | (S)-1-(4-(4-(1-((R)-1-cy...)
Affinity DataIC50: 5.50E+3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK3 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Array Biopharma

US Patent
LigandPNGBDBM455552(US10730880, Example 218 | (S)-1-(4-(4-(1-((R)-1-cy...)
Affinity DataIC50: 5.50E+3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK3 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent